{"id":41146,"date":"2025-12-09T21:00:00","date_gmt":"2025-12-09T14:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=41146"},"modified":"2025-12-09T21:00:00","modified_gmt":"2025-12-09T14:00:00","slug":"neurophet-introduced-use-cases-of-its-ai-based-brain-imaging-analysis-solutions-at-the-seacure-symposium-hosted-by-nanyang-technological-university-in-singapore","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=41146","title":{"rendered":"Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1954882\/Neurophet_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer&#8217;s disease treatments<\/li>\n<li>Highlighted clinical value of Neurophet AQUA AD\u2026To accelerate efforts across healthcare institutions in <span class=\"xn-location\">Southeast Asia<\/span><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 9, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 9th that it participated in a symposium held on the 28th of last month (local time). The event was hosted by the Southeast Asian Consortium on Neurocognition, Neuroimaging and Biomarker Research (SEACURE) at <span class=\"xn-org\">Nanyang Technological University<\/span> (NTU), <span class=\"xn-location\">Singapore<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mma.prnasia.com\/media2\/2840212\/Hyunkook_Lim__CMO_of_Neurophet__delivering_a_presentation_at_the_SEACURE_symposium.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2840212\/Hyunkook_Lim__CMO_of_Neurophet__delivering_a_presentation_at_the_SEACURE_symposium.jpg?p=medium600\" title=\"Hyunkook Lim, CMO of Neurophet, delivering a presentation at the SEACURE symposium.\" alt=\"Hyunkook Lim, CMO of Neurophet, delivering a presentation at the SEACURE symposium.\" \/> <\/a> <br \/><span>Hyunkook Lim, CMO of Neurophet, delivering a presentation at the SEACURE symposium.<\/span><\/p>\n<\/div>\n<p>At the symposium, Neurophet operated an exhibition booth and showcased its major AI-powered brain imaging analysis solutions, including Neurophet AQUA AD, a software that supports monitoring of Alzheimer&#8217;s disease treatment prescription, therapeutic effect, and adverse effects.<\/p>\n<p>During the event, <span class=\"xn-person\">Hyunkook Lim<\/span>, Chief Medical Officer (CMO) of Neurophet and Director of the Catholic Brain Health Center at Yeouido St. Mary&#8217;s Hospital, along with Nagaendran Kandiah, a leading dementia expert and professor at the Lee Kong Chian School of Medicine, NTU, presented detailed use cases and clinical research outcomes involving Neurophet&#8217;s AI-based brain imaging analysis solutions.<\/p>\n<p><span class=\"xn-person\">Hyunkook Lim<\/span>, CMO of Neurophet, delivered a presentation titled &#8220;Neurophet a Game-Changer in Clinical Practice: Real-World Cases of Dementia Treatment Efficacy &amp; Side Effect Management.&#8221; He highlighted real-world cases from clinical settings in Korea using Neurophet AQUA AD and emphasized its clinical value in enhancing the safety of Alzheimer&#8217;s disease treatment administration.<\/p>\n<p>Professor Nagaendran Kandiah presented on the topic &#8220;Automatic Brain Segmentation in Cognitive Impairment: Validation of AI-based AQUA Software in the Southeast Asian BIOCIS Cohort.&#8221; His detailed research finding demonstrated the clinical validity of Neurophet AQUA, a neurodegeneration imaging analysis software, in patients with mild cognitive impairment and dementia.<\/p>\n<p>Jake Junkil Been, Co-CEO of Neurophet, stated, &#8220;By presenting the clinical value of Neurophet AQUA AD at this symposium, we further strengthened the evidence supporting its clinical utility,&#8221; adding, &#8220;We plan to accelerate the expansion of Neurophet AQUA AD across healthcare institutions in the Southeast Asian region.&#8221;<\/p>\n<p>Meanwhile, the symposium concluded successfully with the participation of approximately 220 neurologists across six Southeast Asian countries, including <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Indonesia<\/span>, <span class=\"xn-location\">Malaysia<\/span>, <span class=\"xn-location\">the Philippines<\/span>, <span class=\"xn-location\">Thailand<\/span>, and <span class=\"xn-location\">Vietnam<\/span>.<\/p>\n<p><b>About Neurophet<\/b><\/p>\n<p>Neurophet\u00a0<span>specializes <\/span>in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.<\/p>\n<p>Major products include brain MRI analysis software &#8220;Neurophet AQUA&#8221;, PET Image Quantitative Analysis Software &#8220;Neurophet SCALE PET&#8221;, Brain imaging treatment planning software for electric and magnetic brain stimulation &#8220;Neurophet tES\/TMS LAB&#8221;, Alzheimer&#8217;s Disease treatment prescription and monitoring software &#8220;Neurophet AQUA AD&#8221; for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software &#8220;Neurophet AQUA MS&#8221;.<\/p>\n<p>Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain&#8217;s health and pioneer solutions for brain diseases with AI technology.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1954882\/Neurophet_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer&#8217;s disease treatments<\/li>\n<li>Highlighted clinical value of Neurophet AQUA AD\u2026To accelerate efforts across healthcare institutions in <span class=\"xn-location\">Southeast Asia<\/span><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 9, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 9th that it participated in a symposium held on the 28th of last month (local time). The event was hosted by the Southeast Asian Consortium on Neurocognition, Neuroimaging and Biomarker Research (SEACURE) at <span class=\"xn-org\">Nanyang Technological University<\/span> (NTU), <span class=\"xn-location\">Singapore<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mma.prnasia.com\/media2\/2840212\/Hyunkook_Lim__CMO_of_Neurophet__delivering_a_presentation_at_the_SEACURE_symposium.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2840212\/Hyunkook_Lim__CMO_of_Neurophet__delivering_a_presentation_at_the_SEACURE_symposium.jpg?p=medium600\" title=\"Hyunkook Lim, CMO of Neurophet, delivering a presentation at the SEACURE symposium.\" alt=\"Hyunkook Lim, CMO of Neurophet, delivering a presentation at the SEACURE symposium.\" \/> <\/a> <br \/><span>Hyunkook Lim, CMO of Neurophet, delivering a presentation at the SEACURE symposium.<\/span><\/p>\n<\/div>\n<p>At the symposium, Neurophet operated an exhibition booth and showcased its major AI-powered brain imaging analysis solutions, including Neurophet AQUA AD, a software that supports monitoring of Alzheimer&#8217;s disease treatment prescription, therapeutic effect, and adverse effects.<\/p>\n<p>During the event, <span class=\"xn-person\">Hyunkook Lim<\/span>, Chief Medical Officer (CMO) of Neurophet and Director of the Catholic Brain Health Center at Yeouido St. Mary&#8217;s Hospital, along with Nagaendran Kandiah, a leading dementia expert and professor at the Lee Kong Chian School of Medicine, NTU, presented detailed use cases and clinical research outcomes involving Neurophet&#8217;s AI-based brain imaging analysis solutions.<\/p>\n<p><span class=\"xn-person\">Hyunkook Lim<\/span>, CMO of Neurophet, delivered a presentation titled &#8220;Neurophet a Game-Changer in Clinical Practice: Real-World Cases of Dementia Treatment Efficacy &amp; Side Effect Management.&#8221; He highlighted real-world cases from clinical settings in Korea using Neurophet AQUA AD and emphasized its clinical value in enhancing the safety of Alzheimer&#8217;s disease treatment administration.<\/p>\n<p>Professor Nagaendran Kandiah presented on the topic &#8220;Automatic Brain Segmentation in Cognitive Impairment: Validation of AI-based AQUA Software in the Southeast Asian BIOCIS Cohort.&#8221; His detailed research finding demonstrated the clinical validity of Neurophet AQUA, a neurodegeneration imaging analysis software, in patients with mild cognitive impairment and dementia.<\/p>\n<p>Jake Junkil Been, Co-CEO of Neurophet, stated, &#8220;By presenting the clinical value of Neurophet AQUA AD at this symposium, we further strengthened the evidence supporting its clinical utility,&#8221; adding, &#8220;We plan to accelerate the expansion of Neurophet AQUA AD across healthcare institutions in the Southeast Asian region.&#8221;<\/p>\n<p>Meanwhile, the symposium concluded successfully with the participation of approximately 220 neurologists across six Southeast Asian countries, including <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Indonesia<\/span>, <span class=\"xn-location\">Malaysia<\/span>, <span class=\"xn-location\">the Philippines<\/span>, <span class=\"xn-location\">Thailand<\/span>, and <span class=\"xn-location\">Vietnam<\/span>.<\/p>\n<p><b>About Neurophet<\/b><\/p>\n<p>Neurophet\u00a0<span>specializes <\/span>in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.<\/p>\n<p>Major products include brain MRI analysis software &#8220;Neurophet AQUA&#8221;, PET Image Quantitative Analysis Software &#8220;Neurophet SCALE PET&#8221;, Brain imaging treatment planning software for electric and magnetic brain stimulation &#8220;Neurophet tES\/TMS LAB&#8221;, Alzheimer&#8217;s Disease treatment prescription and monitoring software &#8220;Neurophet AQUA AD&#8221; for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software &#8220;Neurophet AQUA MS&#8221;.<\/p>\n<p>Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain&#8217;s health and pioneer solutions for brain diseases with AI technology.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-41146","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/41146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41146"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/41146\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}